Total Payments
$17,632
2024 Payments
$15,783
Companies
4
Transactions
17
Payment Breakdown by Category
Research$17,517 (99.3%)
Food & Beverage$114.83 (0.7%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $17,517 | 13 | 99.3% |
| Food and Beverage | $114.83 | 4 | 0.7% |
Payments by Type
Research
$17,517
13 transactions
General
$114.83
4 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Eli Lilly and Company | $16,352 | 2 | $0 (2024) |
| AbbVie, Inc. | $1,165 | 11 | $0 (2019) |
| Merck Sharp & Dohme LLC | $103.16 | 3 | $0 (2024) |
| Janssen Research & Development, LLC | $11.67 | 1 | $0 (2020) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $15,783 | 2 | Eli Lilly and Company ($15,748) |
| 2022 | $672.36 | 3 | Eli Lilly and Company ($604.00) |
| 2020 | $11.67 | 1 | Janssen Research & Development, LLC ($11.67) |
| 2019 | $1,165 | 11 | AbbVie, Inc. ($1,165) |
All Payment Transactions
17 individual payment records from CMS Open Payments
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 09/27/2024 | Eli Lilly and Company | — | — | Cash or cash equivalent | $15,748.00 | Research |
| Study: A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO INVESTIGATE THE EFFECT OF LEPODISIRAN ON THE REDUCTION OF MAJOR ADVERSE CARDIOVASCULAR EVENTS IN ADULTS WITH ELEVATED LIPOPROTEIN(A) WHO HAVE ESTABLISHED ATHEROSCLEROTIC CARDIOVASCULAR DISEASE OR ARE AT RISK FOR A FIRST CARDIOVASCULAR EVENT - ACCLAIM-LP(A) | ||||||
| 06/27/2024 | Merck Sharp & Dohme LLC | — | Food and Beverage | In-kind items and services | $34.80 | General |
| Category: CARDIOVASCULAR | ||||||
| 08/09/2022 | Merck Sharp & Dohme LLC | — | Food and Beverage | In-kind items and services | $33.57 | General |
| Category: VACCINE | ||||||
| 08/08/2022 | Merck Sharp & Dohme LLC | — | Food and Beverage | In-kind items and services | $34.79 | General |
| Category: VACCINE | ||||||
| 01/05/2022 | Eli Lilly and Company | — | — | In-kind items and services | $604.00 | Research |
| Study: A PHASE 4, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY EVALUATING THE EFFICACY AND SAFETY OF GALCANEZUMAB VERSUS RIMEGEPANT IN ADULT PARTICIPANTS WITH EPISODIC MIGRAINE | ||||||
| 01/31/2020 | Janssen Research & Development, LLC | — | Food and Beverage | In-kind items and services | $11.67 | General |
| 07/12/2019 | AbbVie, Inc. | Androgel (Drug) | — | In-kind items and services | $39.56 | Research |
| Study: M16-100 • Category: Endocrinology | ||||||
| 07/12/2019 | AbbVie, Inc. | Androgel (Drug) | — | In-kind items and services | $24.52 | Research |
| Study: M16-100 • Category: Endocrinology | ||||||
| 07/12/2019 | AbbVie, Inc. | Androgel (Drug) | — | In-kind items and services | $24.00 | Research |
| Study: M16-100 • Category: Endocrinology | ||||||
| 07/12/2019 | AbbVie, Inc. | Androgel (Drug) | — | In-kind items and services | $23.17 | Research |
| Study: M16-100 • Category: Endocrinology | ||||||
| 04/05/2019 | AbbVie, Inc. | Androgel (Drug) | — | In-kind items and services | $593.80 | Research |
| Study: M16-100 • Category: Endocrinology | ||||||
| 04/05/2019 | AbbVie, Inc. | Androgel (Drug) | — | In-kind items and services | $58.57 | Research |
| Study: M16-100 • Category: Endocrinology | ||||||
| 04/05/2019 | AbbVie, Inc. | Androgel (Drug) | — | In-kind items and services | $36.06 | Research |
| Study: M16-100 • Category: Endocrinology | ||||||
| 04/05/2019 | AbbVie, Inc. | Androgel (Drug) | — | In-kind items and services | $18.86 | Research |
| Study: M16-100 • Category: Endocrinology | ||||||
| 04/05/2019 | AbbVie, Inc. | Androgel (Drug) | — | In-kind items and services | $18.75 | Research |
| Study: M16-100 • Category: Endocrinology | ||||||
| 04/04/2019 | AbbVie, Inc. | Androgel (Drug) | — | In-kind items and services | $204.06 | Research |
| Study: M16-100 • Category: Endocrinology | ||||||
| 04/04/2019 | AbbVie, Inc. | Androgel (Drug) | — | In-kind items and services | $124.07 | Research |
| Study: M16-100 • Category: Endocrinology | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO INVESTIGATE THE EFFECT OF LEPODISIRAN ON THE REDUCTION OF MAJOR ADVERSE CARDIOVASCULAR EVENTS IN ADULTS WITH ELEVATED LIPOPROTEIN(A) WHO HAVE ESTABLISHED ATHEROSCLEROTIC CARDIOVASCULAR DISEASE OR ARE AT RISK FOR A FIRST CARDIOVASCULAR EVENT - ACCLAIM-LP(A) | Eli Lilly and Company | $15,748 | 1 |
| M16-100 | AbbVie, Inc. | $1,165 | 11 |
| A PHASE 4, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY EVALUATING THE EFFICACY AND SAFETY OF GALCANEZUMAB VERSUS RIMEGEPANT IN ADULT PARTICIPANTS WITH EPISODIC MIGRAINE | Eli Lilly and Company | $604.00 | 1 |
About Dr. Mary Bailey, M.D
Dr. Mary Bailey, M.D is a Anatomic Pathology healthcare provider based in Norfolk, Virginia. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 04/25/2007. The National Provider Identifier (NPI) number assigned to this provider is 1174742043.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Mary Bailey, M.D has received a total of $17,632 in payments from pharmaceutical and medical device companies, with $15,783 received in 2024. These payments were reported across 17 transactions from 4 companies. The most common payment nature is "" ($17,517).
Ad
Practice Information
- Specialty Anatomic Pathology
- Other Specialties Anatomic Pathology & Clinical Pathology, Internal Medicine
- Location Norfolk, VA
- Active Since 04/25/2007
- Last Updated 10/29/2018
- Taxonomy Code 207ZP0101X
- Entity Type Individual
- NPI Number 1174742043
Products in Payments
- Androgel (Drug) $1,165
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.